SIRION ACQUIRES US LICENSE TO DEVELOP NEW OPHTHALMIC DRUG

Sirion Therapeutics, Inc., an ophthalmic focused pharmaceutical company, has reached an exclusive licensing agreement with Laboratories Sophia S.A.de C.V. of Mexico for the US rights to develop and market a unique topical solution with the active ingredient cyclosporine A for ophthalmic use. Cyclosporine A is a potent and versatile compound that modulates the body's immune system.

Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34424§ionid=)